Shares of OptiNose Inc (NASDAQ:OPTN) have been given an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. OptiNose’s rating score has improved by 6% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a twelve-month consensus price target of $29.25 for the company and are anticipating that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also given OptiNose an industry rank of 187 out of 265 based on the ratings given to its competitors.

Several research analysts have recently commented on OPTN shares. BMO Capital Markets started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $29.00 price objective for the company. Jefferies Group started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued a “buy” rating and a $27.00 price objective for the company. Piper Jaffray Companies started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued an “overweight” rating and a $27.00 price objective for the company. Finally, Royal Bank of Canada started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $33.00 price objective for the company.

A number of institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN purchased a new position in OptiNose in the fourth quarter worth approximately $5,392,000. American Century Companies Inc. purchased a new position in OptiNose in the fourth quarter worth approximately $1,745,000. Kornitzer Capital Management Inc. KS purchased a new position in OptiNose in the fourth quarter worth approximately $6,040,000. Peregrine Capital Management LLC purchased a new position in OptiNose in the fourth quarter worth approximately $6,314,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in OptiNose in the fourth quarter worth approximately $432,000. Institutional investors own 0.95% of the company’s stock.

OptiNose (OPTN) opened at $18.44 on Tuesday. OptiNose has a 12 month low of $15.01 and a 12 month high of $21.50.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Monday, November 27th. The company reported ($4.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($3.76). analysts expect that OptiNose will post -1.33 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Zacks: OptiNose Inc (OPTN) Given Average Recommendation of “Strong Buy” by Analysts” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/02/09/zacks-optinose-inc-optn-given-average-recommendation-of-strong-buy-by-analysts.html.

OptiNose Company Profile

OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.